EUCTR2019-002414-40-GB进行中（未招募）1 期
A Phase 2, Multi-Center, Open-Label Study to Evaluate Long-term Safety and Efficacy of CXA-10 in Subjects with Pulmonary Arterial Hypertension on Stable Background Therapy: Extension to Study CXA-10-301. - Open label extension of CXA-10 in Pulmonary Arterial Hypertension
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 115
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Evidence of a personally signed and dated informed consent document indicating subject has been informed of all pertinent aspects of the study prior to initiation of any study-required procedures.
- •2. Is willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.
- •3. Has completed the CXA-10-301 study and demonstrated compliance with study medication administration and all study requirements.
- •4. If receiving simvastatin-containing products: simvastatin (Zocor), Vytorin, or any other combination therapy containing simvastatin, simvastatin dose does not exceed 20 mg/day.
- •5. Currently receiving no more than three of the following previously approved PAH therapies: phosphodiesterase type 5 (PDE-5) inhibitors, endothelin receptor antagonists (ERA), soluble guanylate cyclase (sGC) stimulator, prostanoids, prostacyclin receptor agonists.
- •6. Women of childbearing potential and males with partners of childbearing potential must agree to use a reliable method of contraception while taking study medication. Acceptable methods of birth control are defined in the protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 85
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •1. Severe hypotension: systolic blood pressure <90 mmHg (sitting) at Baseline (Visit 1).
- •2. Hypertensive: >160 mmHg systolic or >110 mmHg diastolic (sitting) at Baseline (V1).
- •3. QTcF on supine ECGs at Baseline (V1) of >500 msec.
- •4. Acute myocardial infarction or acute coronary syndrome (ST-Elevation Myocardial Infarction [STEMI], Non STEMI [NSTEMI] and or unstable angina) within the last 90 days prior to Baseline (V1).
- •5. Recent cerebrovascular accident/transient ischemic attack (CVA/TIA) within the last 90 days prior to Baseline (V1).
- •6. Recent hospitalization for left heart failure within the last 90 days prior to Baseline (V1).
- •7. Clinically significant aortic or mitral valve disease defined as greater than mild regurgitation or mild stenosis; pericardial constriction; restrictive or constrictive cardiomyopathy; left ventricular dysfunction (LVEF < 50%); left ventricular outflow obstruction; symptomatic coronary artery disease; autonomic hypotension; or fluid depletion, in the opinion of the investigator.
- •8. Chronic atrial fibrillation and life-threatening cardiac arrhythmias.
- •9. Personal or family history of congenital prolonged QTc syndrome or sudden unexpected death due to a cardiac reason.
- •10. Clinically significant anemia in the opinion of the investigator that precludes enrollment into this study, or Hb <9 gm/dl.
- •11. Severe hepatic impairment (Child-Pugh class C with or without cirrhosis) at Baseline (V1) or active chronic hepatitis.
- •12. Received intravenous inotropes within 2 weeks prior to Baseline (V1) (e.g. dopamine, dobutamine).
- •13. History of angina pectoris or other condition that was treated with long or short acting nitrates <12 weeks of Baseline (V1).
- •14. History of herbal or natural medication use (including fish oil) within 2 weeks or 5 half-lives, whichever is longer, prior to Baseline (V1).
- •15. Received prednisone at doses >15 mg/ day or changes in immunosuppressive medications <12 weeks prior to Baseline (V1).
- •16. Currently taking a drug that may affect the assay measurement of serum creatinine (e.g. cimetidine, Bactrim, Pyridium).
- •17. Newly prescribed drug or increased dose of an existing drug that is known to prolong the QTc interval and has been associated with Torsades de Pointes (TdP) identified in the CredibleMeds.org website list as known risk (KR) of TdP.
- •Note: Stable doses of drugs classified as conditional risk (CR) of TdP or possible risk (PR) of TdP are permitted (i.e., subject has received the same dose and regimen for at least 30 days prior to Baseline (V1) with no anticipated changes to the dose or regimen during the course of the study).
- •18. Currently taking dimethyl fumarate (Tecfidera™).
- •19. Any of the following laboratories abnormal and unresolved in CXA-10-301:
- •a. Absolute lymphocyte counts < 0.5 x 10^9 cells/L.
- •b. Aspartate aminotransferase and/or alanine aminotransferase > 3.0X upper limit of normal (ULN), alkaline phosphatase > 2X ULN of liver origin, and total bilirubin >2X ULN. If all liver function tests (LFTs) are within normal limits and total bilirubin is elevated, examination of direct and indirect bilirubin may be conducted to evaluate for Rotor’s/Gilbert’s Syndrome. Subjects with Rotor’s/Gilbert’s Syndrome may be enrolled.
- •c. eGFR < 30 mL/min/1.73 m2 (estimated by Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] Creatinine/Cystatin C 2012 algorithm) at Baseline (Visit 1).
- •20. Females who are pregnant or breastfeeding, or who are trying to conceive.
- •21. Recent (within 1
研究者
相似试验
进行中（未招募）
1 期
Safety and Efficacy of AT-1501 in Patients with IgAIgA NephropathyMedDRA version: 20.1Level: PTClassification code 10029151Term: NephropathySystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2021-004795-34-ESEledon Pharmaceuticals, Inc42
进行中（未招募）
1 期
Safety and Efficacy of AT-1501 in Patients with IgAIgA NephropathyMedDRA version: 20.1Level: PTClassification code 10029151Term: NephropathySystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2021-004795-34-PLEledon Pharmaceuticals, Inc42
尚未招募
2 期
A Phase 2a, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of AT-1501 in Patients with IgA NephropathyIgA Nephropathy (IgAN)SLCTR/2022/010Eledon Pharmaceuticals, Inc
进行中（未招募）
2 期
Study to Evaluate the Efficacy and Safety of CYH33 in Patient with Recurrent/Persistent Ovary, Fallopian Tube or Primary Peritoneal Clear Cell CarcinomaJPRN-jRCT2031210216Kitano Tina36
进行中（未招募）
1 期
A Phase 2, Multi-Center, unblinded study to evaluate the intermediate/long term safety and effectiveness of AIR001 in subjects with high blood pressure in the blood vessels in the lungsMedDRA version: 16.0Level: PTClassification code 10037400Term: Pulmonary hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersPulmonary Arterial HypertensionEUCTR2012-000153-31-ITAires Pharmaceuticals, Inc90